Potential Neuroprotective Strategies for Experimental Spinal Cord Injury

  • Akhlaq A. Farooqui


Spinal cord injury (SCI) is a complex and devastating clinical condition that produces loss of motor and sensory functions below the injury site, often affecting young and healthy individuals throughout the world (Beattie et al., 2000). Functional recovery is very limited because injured axons within the brain and spinal cord are unable to regenerate spontaneously and therapeutic strategies to reestablish lost neuronal connections in spinal cord injury patients are currently unavailable (Schwab et al., 2006; Fouad and Pearson, 2004; Fouad and Tse, 2008). Several factors, including myelin-associated neurite growth inhibitors3, myelin-associated glycoprotein (MAG), myelin-associated glycoprotein (Nogo), and oligodendrocyte-myelin glycoprotein (OMgp), block the regeneration of injured neurons (McKerracher and Winton, 2002; Watkins and Barres, 2002; Filbin, 2003; Watkins and Barres, 2002).


Spinal Cord Spinal Cord Injury Glucocorticoid Receptor Axonal Regeneration Injured Spinal Cord 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ala T, Romero S, Knight F, Feldt K, Frey WH 2nd (1990) GM-1 treatment of Alzheimer’s disease. A pilot study of safety and efficacy. Arch Neurol 47:1126–1130PubMedCrossRefGoogle Scholar
  2. Anderson DK, Braughler JM, Hall ED, Waters TR, McCall JM, Means ED (1988) Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury. J Neurosurg 69:562–567PubMedCrossRefGoogle Scholar
  3. Anderson DK, Hall ED, Braughler JM, McCall JM, Means ED (1991) Effect of delayed administration of U74006F (tirilazad mesylate) on recovery of locomotor function after experimental spinal cord injury. J Neurotrauma 8:187–192PubMedCrossRefGoogle Scholar
  4. Anderson DK, Hall ED (1994) Lipid hydrolysis and free radical formation in central nervous system trauma. In: Salzman SK, Faden AI (eds) The neurobiology of central nervous system trauma. Oxford University Press, Oxford, pp 131–138Google Scholar
  5. Ao Q, Wang AJ, Chen GO, Wang ST, Zuo HC, Zhang XF (2007) Combined transplantation of neural stem cells and olfactory ensheathing cells for the repair of spinal cord injuries. Med Hypotheses 69:1234–1237PubMedCrossRefGoogle Scholar
  6. Aslan A, Cemek M, Buyukokuroglu ME, Altunbas K, Bas O, Yurumez Y, Cosar M (2009) Dantrolene can reduce secondary damage after spinal cord injury. Eur Spine J 26 May 2009 [Epub ahead of print]Google Scholar
  7. Baptiste DC, Austin JW, Zhao W, Nahirny A, Sugita S, Fehlings MG (2009) Systemic polyethylene glycol promotes neurological recovery and tissue sparing in rats after cervical spinal cord injury. J Neuropathol Exp Neurol 18 May 2009 [Epub ahead of print]Google Scholar
  8. Bartolomei JC, Greer CA (2000) Olfactory ensheathing cells: bridging the gap in spinal cord injury. Neurosurgery 47:1057–1069PubMedCrossRefGoogle Scholar
  9. Beattie MS, Farooqui AA, Bresnahan JC (2000) Review of current evidence for apoptosis after spinal cord injury. J Neurotrauma 17:915–925PubMedCrossRefGoogle Scholar
  10. Behrman AL, Bowden MG, Nair PM (2006) Neuroplasticity after spinal cord injury and training: an emerging paradigm shift in rehabilitation and walking recovery. Phys Ther 86:1406–1425PubMedCrossRefGoogle Scholar
  11. Blesch and Tuszynski (2003) Cellular GDNF delivery promotes growth of motor and dorsal column sensory axons after partial and complete spinal cord transections and induces remyelination. J Comp Neurol 467:403–417CrossRefGoogle Scholar
  12. Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study. N Engl J Med 322:1405–1411PubMedCrossRefGoogle Scholar
  13. Buki A, Farkas O, Doczi T, Povlishock JT (2003) Preinjury administration of the calpain inhibitor MDL-28170 attenuates traumatically induced axonal injury. J Neurotrauma 20:261–268PubMedCrossRefGoogle Scholar
  14. Bunge MB (2008) Novel combination strategies to repair the injured mammalian spinal cord. J Spinal Cord Med 31:262–269PubMedGoogle Scholar
  15. Carvalho MO, Barros Filho TE, Tebet MA (2008) Effects of methylprednisolone and ganglioside GM-1 on a spinal lesion: a functional analysis. Clinics (Sao Paulo) 63:375–380Google Scholar
  16. Ceylan S, Ilbay K, Baykal S, Ceylan S, Sener U, Ozmenoğlu M, Kalelioğlu M, Aktürk F, Komsuoğlu SS, Ozoran A (1992) Treatment of acute spinal cord injuries: comparison of thyrotropin-releasing hormone and nimodipine. Res Exp Med (Berl) 192:23–33CrossRefGoogle Scholar
  17. Chang CM, Lee MH, Wang TC, Weng HH, Chung CY, Yang JT (2009) Brain protection by methylprednisolone in rats with spinal cord injury. Neuroreport 20:968–972PubMedCrossRefGoogle Scholar
  18. Chinnock P, Roberts I (2005) Gangliosides for acute spinal cord injury. Cochrane Database Syst Rev 2:CD004444PubMedGoogle Scholar
  19. Chvatal SA, Kim YT, Bratt-Leal AM, Lee H, Bellamkonda RV (2008) Spatial distribution and acute anti-inflammatory effects of methylprednisolone after sustained local delivery to the contused spinal cord. Biomaterials 29:1967–1975PubMedCrossRefGoogle Scholar
  20. Dasari VR, Spomar DG, Gondi CS, Sloffer CA, Saving KL, Gujrati M, Rao JS, Dinh DH (2007) Axonal remyelination by cord blood stem cells after spinal cord injury. J Neurotrauma 24:391–410PubMedCrossRefGoogle Scholar
  21. Dasari VR, Veeravalli KK, Tsung AJ, Gondi CS, Gujrati M, Dinh D, Rao JS (2009) Neuronal apoptosis inhibited by cord blood stem cells after spinal cord injury. J Neurotrauma 26 May 2009 [Epub ahead of print]Google Scholar
  22. Ding Y, Kastin AJ, Pan W (2005) Neural plasticity after spinal cord injury. Curr Pharm Des 11:1441–1450PubMedCrossRefGoogle Scholar
  23. Ditor DS, John SM, Roy J, Marx JC, Kittmer C, Weaver LC (2007) Effects of polyethylene glycol and magnesium sulfate administration on clinically relevant neurological outcomes after spinal cord injury in the rat. J Neurosci Res 85:1458–1467PubMedCrossRefGoogle Scholar
  24. Domeniconi M, Filbin MT (2005) Overcoming inhibitors in myelin to promote axonal regeneration. J Neurol Sci 233:43–47PubMedCrossRefGoogle Scholar
  25. Eftekharpour E, Karimi-Abdolrezaee S, Fehlings MG (2008) Current status of experimental cell replacement approaches to spinal cord injury. Neurofocus 24:E19Google Scholar
  26. Farooqui AA, Yang HC, Horrocks LA (1997) Involvement of phospholipase A2 in neurodegeneration. Neurochem Int 30:517–522PubMedCrossRefGoogle Scholar
  27. Farooqui AA, Litsky ML, Farooqui T, Horrocks LA (1999) Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders. Brain Res Bull 49:139–153PubMedCrossRefGoogle Scholar
  28. Farooqui AA, Ong WY, Horrocks LA (2004) Biochemical aspects of neurodegeneration in human brain: involvement of neural membrane phospholipids and phospholipases A2. Neurochem Res 29:1961–1977PubMedCrossRefGoogle Scholar
  29. Farooqui AA, Ong WY, Horrocks LA (2006) Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 58:591–620PubMedCrossRefGoogle Scholar
  30. Farooqui AA, Horrocks LA (2007) Glycerophospholipids in brain. Springer, New York, NYCrossRefGoogle Scholar
  31. Favaron M, Manev H, Alho H, Bertolino M, Ferret B, Guidotti A, Costa E (1988) Gangliosides prevent glutamate and kainate neurotoxicity in primary neuronal cultures of neonatal rat cerebellum and cortex. Proc Natl Acad Sci USA 85:7351–7355PubMedCrossRefGoogle Scholar
  32. Festoff BW, Ameenuddin S, Arnold PM, Wong A, Santacruz KS, Citron BA (2006) Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 97:1314–1326PubMedCrossRefGoogle Scholar
  33. Filbin MT (2003) Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci 4:703–713PubMedCrossRefGoogle Scholar
  34. Fouad K, Pearson K (2004) Restoring walking after spinal cord injury. Prog Neurobiol 73:107–126PubMedCrossRefGoogle Scholar
  35. Fouad K, Tse A (2008) Adaptive changes in the injured spinal cord and their role in promoting functional recovery. Neurol Res 30:17–27PubMedCrossRefGoogle Scholar
  36. Franssen EH, de Bree FM, Verhaagen J (2007) Olfactory ensheathing glia: their contribution to primary olfactory nervous system regeneration and their regenerative potential following transplantation into the injured spinal cord. Brain Res Rev 56:236–258PubMedCrossRefGoogle Scholar
  37. Furukawa S, Furukawa Y (2007) FGF-2-treatment improves locomotor function via axonal regeneration in the transected rat spinal cord. Brain Nerve 59:1333–1339PubMedGoogle Scholar
  38. Garcia-Martinez EM, Sanz-Blasco S, Karachitos A, Bandez MJ, Fernandez-Gomez FJ, Perez-Alvarez S, de Mera RM, Jordan MJ, Aguirre N, Galindo MF, Villalobos C, Navarro A, Kmita H, Jordán J (2010) Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem Pharmacol 79:239–250PubMedCrossRefGoogle Scholar
  39. Geisler FH, Dorsey FC, Coleman WP (1991) Recovery of motor function after spinal-cord injury–a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med 324:1829–1838PubMedCrossRefGoogle Scholar
  40. Geisler FH, Dorsey FC, Coleman WP (1993) Past and current clinical studies with GM-1 ganglioside in acute spinal cord injury. Ann Emerg Med 22:1041–1047PubMedCrossRefGoogle Scholar
  41. Geisler FH (1998) Clinical trials of pharmacotherapy for spinal cord injury. Ann NY Acad Sci 845:374–381PubMedCrossRefGoogle Scholar
  42. Hall ED (1988) Effects of the 21-aminosteroid U74006F on posttraumatic spinal cord ischemia in cats. J Neurosurg 68:462–465PubMedCrossRefGoogle Scholar
  43. Hall ED, Andrus PK, Smith SL, Oostveen JA, Scherch HM, Lutzke BS, Raub TJ, Sawada GA, Palmer JR, Banitt LS, Tustin JS, Belonga KL, Ayer DE, Bundy GL (1996) Neuroprotective efficacy of microvascularly-localized versus brain-penetrating antioxidants. Acta Neurochir Suppl 66:107–113PubMedGoogle Scholar
  44. Hashimoto T, Fukuda N (1991) Effect of thyrotropin-releasing hormone on the neurologic impairment in rats with spinal cord injury: treatment starting 24 h and 7 days after injury. Eur J Pharmacol 203:25–32PubMedCrossRefGoogle Scholar
  45. Hawryluk GW, Rowland J, Kwon BK, Fehlings MG (2008) Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Nurosurg Focus 25:E14CrossRefGoogle Scholar
  46. Hsu JY, Bourguignon LY, Adams CM, Peyrollier K, Zhang H, Fandel T, Cun CL, Werb Z, Noble-Haeusslein LJ (2008) Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord. J Neurosci 28:13467–13477PubMedCrossRefGoogle Scholar
  47. Hu WH, Qiang WA, Li F, Liu N, Wang GO, Wang HY, Wan XS, Liao WH, Liu JS, Jen MF (2000) Constitutive and inducible nitric oxide synthases after dynorphin-induced spinal cord injury. J Chem Neuroanat 17:183–197PubMedCrossRefGoogle Scholar
  48. Hua XY, Svensson CI, Matsui T, Fitzsimmons B, Yaksh TL, Webb M (2005) Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhibiting p38 MAPK in spinal microglia. Eur J Neurosci 22:2431–2440PubMedCrossRefGoogle Scholar
  49. Huang WL, King VR, Dyall SC, Ward RE, Lal N, Priestley JV, Michael-Titus AT (2007) A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain 130:3004–3019PubMedCrossRefGoogle Scholar
  50. Huang W, Bhavsar A, Ward RE, Hall JC, Priestley JV, Michael-Titus AT (2009) Arachidonyl trifluoromethyl ketone is neuroprotective after spinal cord injury. J Neurotrauma 16 Apr 2009 [Epub ahead of print]Google Scholar
  51. Ikeda O, Murakami M, Ino H, Yamazaki M, Nemoto T, Koda M, Nakayama C, Moriya H (2001) Acute up-regulation of brain-derived neurotrophic factor expression resulting from experimentally induced injury in the rat spinal cord. Acta Neuropathol 102:239–245PubMedGoogle Scholar
  52. Ito M, Natsume A, Takeuchi H, Shimato S, Ohno M, Wakabayashi T, Yoshida J (2009) Type I interferon inhibits astrocytic gliosis and promotes functional recovery after spinal cord injury by deactivation of the MEK/ERK Pathway. J Neurotrauma 26:41–53PubMedCrossRefGoogle Scholar
  53. Jacob PL, Nash MS (2004) Exercise recommendations for individuals with spinal cord injury. Sport Med 34:727–751CrossRefGoogle Scholar
  54. Jones LL, Oudega M, Bunge MB, Tuszynski MH (2001) Neurotrophic factors, cellular bridges and gene therapy for spinal cord injury. J Physiol 533:83–89PubMedCrossRefGoogle Scholar
  55. Jones LL, Margolis RU, Tuszynski MH (2003) The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury. Exp Neurol 182:399–411PubMedCrossRefGoogle Scholar
  56. Kim SS, Kong PJ, Kim BS, Sheen DH, Nam SY, Chun W (2004) Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res 27:314–318PubMedCrossRefGoogle Scholar
  57. Kim HM, Hwang DH, Lee JE, Kim SU, Kim BG (2007) Stem cell-based cell therapy for spinal cord injury. Cell Transplant 16:355–364PubMedCrossRefGoogle Scholar
  58. Kim HM, Hwang DH, Lee JE, Kim SU, Kim BG (2009) Ex vivo VEGF delivery by neural stem cells enhances proliferation of glial progenitors, angiogenesis, and tissue sparing after spinal cord injury. PLoS One 4:e4987PubMedCrossRefGoogle Scholar
  59. Kim YT, Caldwell JM, Bellamkonda RV (2009) Nanoparticle-mediated local delivery of Methylprednisolone after spinal cord injury. Biomaterials 30:2582–2590PubMedCrossRefGoogle Scholar
  60. Kim HS, Suh YH (2009) Minocycline and neurodegenerative diseases. Behav Brain Res 196:168–179PubMedCrossRefGoogle Scholar
  61. King VR, Huang WL, Dyall SC, Curran OE, Priestley JV, Michael-Titus AT (2006) Omega-3 fatty acids improve recovery, whereas omega-6 fatty acids worsen outcome, after spinal cord injury in the adult rat. J Neurosci 26:4672–4680PubMedCrossRefGoogle Scholar
  62. Koob AO, Colby JM, Borgens RB (2008) Behavioral recovery from traumatic brain injury after membrane reconstruction using polyethylene glycol. J Biol Eng 2:9PubMedCrossRefGoogle Scholar
  63. Kubo T, Hata K, Yamaguchi A, Yamashita T (2008) Rho-ROCK inhibitors as emerging strategies to promote nerve regeneration. Curr Pharm Des 13:2493–2499CrossRefGoogle Scholar
  64. Kwok JC, Afshari F, Garcia-Alias G, Fawcett JW (2008) Proteoglycans in the central nervous system: plasticity, regeneration and their stimulation with chondroitinase ABC. Restor Neurol Neurosci 26:131–145PubMedGoogle Scholar
  65. Kwon BK, Roy J, Lee JH, Okon EB, Zhang H, Marx JC, Kindy MS (2009) Magnesium chloride in a polyethylene glycol formulation as a neuroprotective therapy for acute spinal cord injury: preclinical refinement and optimization. J Neurotrauma 24 Mar 2009 [Epub ahead of print]Google Scholar
  66. Lang-Lazdunski L, Biondeau N, Jarretou G, Heurteaux C (2003) Linolenic acid prevents neuronal cell death and paraplegia after transient spinal cord ischemia in rats. J Vasc Surg 38:564–575PubMedCrossRefGoogle Scholar
  67. Latorre E, Collado MP, Fernández I, Aragonés MD, Catalán RE (2003) Signaling events mediating activation of brain ethanolamine plasmalogen hydrolysis by ceramide. Eur J Biochem 270:36–46PubMedCrossRefGoogle Scholar
  68. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazunski M (2000) Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 19:1784–1793PubMedCrossRefGoogle Scholar
  69. Ledeen RW, Wu G (2002) Ganglioside function in calcium homeostasis and signaling. Neurochem Res 27:637–647PubMedCrossRefGoogle Scholar
  70. Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, Oh YJ, Markelonis GJ, Oh TH (2003) Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 20:1017–1027PubMedCrossRefGoogle Scholar
  71. Lee JM, Yan P, Xiao Q, Chen S, Lee KY, Hsu CH, Xu J (2008) Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury. J Neurosci 28:3141–3149PubMedCrossRefGoogle Scholar
  72. Lee MY, Chen L, Toborek M (2009) Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury. J Neurosci Res 87:937–947PubMedCrossRefGoogle Scholar
  73. Leon A, Facci L, Toffano G, Sonnino S, Tettamanti G (1981) Activation of Na+, K+-ATPase by nanomolar concentrations of GM1 ganglioside. J Neurochem 37:350–357PubMedCrossRefGoogle Scholar
  74. Lingor P, Teusch N, Schwarz K, Mueller R, Mack H, Bahr M, Mueller BK (2007) Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem 103:181–191PubMedGoogle Scholar
  75. Liu NK, Zhang YP, Titsworth WL, Jiang X, Han S, Lu PH, Shields CB, Xu XM (2006) A novel role of phospholipase A2 in mediating spinal cord secondary injury. Ann Neurol 59:606–619PubMedCrossRefGoogle Scholar
  76. Liu Y, Wang X, Lu CC, Kerman R, Steward O, Xu XM, Zou Y (2008a) Repulsive Wnt signaling inhibits axon regeneration after CNS injury. J Neurosci 28:8376–8382PubMedCrossRefGoogle Scholar
  77. Liu WL, Lee YH, Tsai SY, Hsu CY, Sun YY, Yang LY, Tsai SH, Yang WC (2008b) Methylprednisolone inhibits the expression of glial fibrillary acidic protein and chondroitin sulfate proteoglycans in reactivated astrocytes. Glia 56:1390–1400PubMedCrossRefGoogle Scholar
  78. Lu J, Ashwell K (2002) Olfactory ensheathing cells: their potential use for repairing the injured spinal cord. Spine (Phila Pa 1978) 27:887–892PubMedCrossRefGoogle Scholar
  79. Lukáčová N, Kolesárová M, Kuchárová K, Pavel J, Kolesár D, Radoňák J, Maršala M, Chalimoniuk M, Langfort J, Maršala J (2005) The effect of a spinal cord hemisection on changes in nitric oxide synthase pools in the site of injury and in regions located far away from the injured site. Cell Mol Neurobiol 26:1365–1383CrossRefGoogle Scholar
  80. Lukacova N, Davidova A, Kolesar D, Kolesarova M, Schreiberova A, Lackova M, Krizanova O, Marsala M, Marsala J (2008) The effect of N-nitro-L-arginine and aminoguanidine treatment on changes in constitutive and inducible nitric oxide synthases in the spinal cord after sciatic nerve transection. Int J Mol Med 21:413–421PubMedGoogle Scholar
  81. Lynskey JV, Belanger A, Jung R (2008) Activity-dependent plasticity in spinal cord injury. J Rehabil Res Dev 45:229–240PubMedCrossRefGoogle Scholar
  82. Machado LS, Kozak A, Erqul A, Hess DC, Borlougan CV, Fagan SC (2006) Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC 7:56Google Scholar
  83. Marchand F, Tsantoulas C, Singh D, Grist J, Clark AK, Bradbury EJ, McMahon SB (2009) Effects of Etanercept and Minocycline in a rat model of spinal cord injury. Eur J Pain 13:673–681PubMedCrossRefGoogle Scholar
  84. Marsala J, Orendacova J, Lukacova N, Vanicky I (2007) Traumatic injury of the spinal cord and nitric oxide. Prog Brain Res 161:171–183PubMedCrossRefGoogle Scholar
  85. McKerracher L, Winton MJ (2002) Nogo on the go. Neuron 36:345–348PubMedCrossRefGoogle Scholar
  86. Melero-Fernández de Mera RM, García-Martínez E, Fernández-Gómez FJ, Hernández-Guijo JM, Aguirre N, Galindo MF, Jordán J (2008) Rev. Neurol 47:31–38Google Scholar
  87. Michael-Titus AT (2007) Omega-3 fatty acids and neurological injury. Prost Leukot Essent Fatty Acids 77:295–300CrossRefGoogle Scholar
  88. Mitcho K, Kanko JR (1999) Acute care management of spinal cord injuries. Crit Care Nurse 22:60–79Google Scholar
  89. Miyashita T, Koda M, Kitajo K, Yamazaki M, Takahashi K, Kikuchi A, Yamashita T (2009) Wnt-Ryk signaling mediates axon growth inhibition and limits functional recovery after spinal cord injury. J Neurotrauma 27 May 2009 [Epub ahead of print]Google Scholar
  90. Monga V, Meena CL, Kaur N, Jain R (2008) Chemistry and biology of thyrotropin-releasing hormone (TRH) and its analogs. Curr Med Chem 15:18–33CrossRefGoogle Scholar
  91. Moriwaki A, Nishida K, Matsushita M, Ozaki T, Kunisada T, Yoshida A, Inoue H, Matsui H (2005) Calpain inhibitors prevent neuronal cell death and ameliorate motor disturbances after compression-induced spinal cord injury in rats. J Neurotrauma 22:398–406PubMedCrossRefGoogle Scholar
  92. Murphy M (1999) Traumatic spinal cord injury: an acute care rehabilitation perspective. Crit Care Nurse Q 22:51–59Google Scholar
  93. Noble LJ, Donovan F, Igarashi T, Gousseo S, Werb Z (2002) Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 22:7526–7535PubMedGoogle Scholar
  94. Olivas AD, Noble-Haeusslein LJ (2006) Phospholipase A2 and spinal cord injury: a novel target for therapeutic intervention. Ann Neurol 59:577–579PubMedCrossRefGoogle Scholar
  95. Park JY, Kim HY, Jou I, Park SM (2008) GM1 induces p38 and microtubule dependent ramification of rat primary microglia in vitro. Brain Res 1244:13–23PubMedCrossRefGoogle Scholar
  96. Partington CR, Daly JW (1979) Effect of gangliosides on adenylate cyclase activity in rat cerebral cortical membranes. Mol Pharmacol 15:484–491PubMedGoogle Scholar
  97. Phillis JW, O’Regan MH (1995) GM1 ganglioside inhibits ischemic release of amino acid neurotransmitters from rat cortex. Neuroreport 6:2010–2012PubMedCrossRefGoogle Scholar
  98. Pizzi MA, Crowe MJ (2007) Matrix metalloproteinases and proteoglycans in axonal regeneration. Exp Neurol 204:496–511PubMedCrossRefGoogle Scholar
  99. Pruzanski W, Greenwald RA, Street IP, Laliberte F, Stefanski E, Vadas P (1992) Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. Biochem Pharmacol 44:1165–1170PubMedCrossRefGoogle Scholar
  100. Pyo H, Joe E, Tung S, Lee SH, Jou I (1999) Gangliosides activate cultured rat brain microglia. J Biol Chem 274:34584–34589PubMedCrossRefGoogle Scholar
  101. Ravikumar R, Fugaccia I, Scheff SW, Geddes JW, Srinivasan C, Toborek M (2005) Nicotine attenuates morphological deficits in a contusion model of spinal cord injury. J Neurotrauma 22:240–251PubMedCrossRefGoogle Scholar
  102. Ray SK, Hogan EL, Banik NL (2003) Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. Brain Res Brain Res Rev 42:169–185PubMedCrossRefGoogle Scholar
  103. Riegger T, Conrad S, Liu K, Schluesener HJ, Adibzahdeh M, Schwab JM (2007) Spinal cord injury-induced immune depression syndrome (SCI-IDS). Eur J Neurosci 25:1743–1747PubMedCrossRefGoogle Scholar
  104. Riegger T, Conrad S, Schluesener HJ, Kaps HP, Badke A, Baron C, Gerstein J, Dietz K, Abdizahdeh M, Schwab JM (2009) Immune depression syndrome following human spinal cord injury (SCI): a pilot study. Neuroscience 158:1194–1199PubMedCrossRefGoogle Scholar
  105. Ruff RL, McKerracher L, Selzer ME (2008) Repair and neurorehabilitation strategies for spinal cord injury. Ann NY Acad Sci 1142:1–20PubMedCrossRefGoogle Scholar
  106. Sadowsky CL, McDonald JW (2009) Activity-based restorative therapies: concepts and applications in spinal cord injury-related neurorehabilitation. Dev Disabil Res Rev 15:112–126PubMedCrossRefGoogle Scholar
  107. Schmid D, Burmester GR, Tripmacher R, Fici G, von Voigtlander P, Buttgereit F (2001) Short-term effects of the 21-aminosteroid lazaroid tirilazad mesylate (PNU-74006F) and the pyrrolopyrimidine lazaroid PNU-101033E on energy metabolism of human peripheral blood mononuclear cells. Biosci Rep 21:101–110PubMedCrossRefGoogle Scholar
  108. Schröter A, Lustenberger RM, Obermair FJ, Thallmair M (2009) High-dose corticosteroids after spinal cord injury reduce neural progenitor cell proliferation. Neuroscience 161:753–763PubMedCrossRefGoogle Scholar
  109. Schwab JM, Brechtel K, Mueller CA, Failli V, Kaps HP, Tuli SK, Schluesener HJ (2006) Experimental strategies to promote spinal cord regeneration––an integrative perspective. Prog Neurobiol 78:91–116PubMedCrossRefGoogle Scholar
  110. Schumacher PA, Siman RG, Fehlings MG (2000) Pretreatment with calpain inhibitor CEP-4143 inhibits calpain I activation and cytoskeletal degradation, improves neurological function, and enhances axonal survival after traumatic spinal cord injury. J Neurochem 74:1646–1655PubMedCrossRefGoogle Scholar
  111. Sharma HS, Badgaiyan RD, Alm P, Mohanty S, Wiklund L (2005) Neuroprotective effects of nitric oxide synthase inhibitors in spinal cord injury-induced pathophysiology and motor functions: an experimental study in the rat. Ann NY Acad Sci 1053:422–434PubMedCrossRefGoogle Scholar
  112. Sharma HS, Nyberg F, Gordh T, Alm P (2006) Topical application of dynorphin A (1–17) antibodies attenuates neuronal nitric oxide synthase up-regulation, edema formation, and cell injury following focal trauma to the rat spinal cord. Acta Neurochir Suppl 96:309–315PubMedCrossRefGoogle Scholar
  113. Shioiri Y, Kurimoto A, Ako T, Daikoku S, Ohtake A, Ishida H, Kiso M, Suzuki K, Kanie O (2009) Energy-resolved structural details obtained from gangliosides. Anal Chem 81:139–145PubMedCrossRefGoogle Scholar
  114. Soderquist RG, Milligan ED, Sloane EM, Harrison JA, Douvas KK, Potter JM, Huges TS, Chavez RA, Johnson K, Watkins LR, Mahoney MJ (2008) PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. J Biomed Mater Res [Epub ahead of print]Google Scholar
  115. Sohn H, Kim YS, Kim HT, Kim CH, Cho EW, Kang HY, Kim NS, Kim CH, Ryu SE, Lee JH, Ko JH (2006) Ganglioside GM3 is involved in neuronal cell death. FASEB J 20:1248–1250PubMedCrossRefGoogle Scholar
  116. Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z (2004) Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport 15:2181–2184PubMedCrossRefGoogle Scholar
  117. Song XY, Li F, Zhang FH, Zhong JH, Zhou XF (2008 Mar 5) 2008. Peripherally-derived BDNF promotes regeneration of ascending sensory neurons after spinal cord injury. PLoS One 3(3):e1707Google Scholar
  118. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, Ramer MS, Tetzlaff W (2004) Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 24:2182–2190PubMedCrossRefGoogle Scholar
  119. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W (2005) Minocycline as a neuroprotective agent. Neuroscientist 11:308–322PubMedCrossRefGoogle Scholar
  120. Svennerholm L (1994) Gangliosides––a new therapeutic agent against stroke and Alzheimer’s disease. Life Sci 55:2125–2134PubMedCrossRefGoogle Scholar
  121. Tan AM, Zhao P, Waxman SG, Hains BC (2009) Early microglial inhibition preemptively mitigates chronic pain development after experimental spinal cord injury. J Rehabi Res Dev 46:123–133CrossRefGoogle Scholar
  122. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, Woodard EJ, Snyder EY, Eichler ME, Friedlander RM (2004) Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA 101:3071–3076PubMedCrossRefGoogle Scholar
  123. Thorell WE, Leibrock LG, Agrawal SK (2002) Role of RyRs and IP3 receptors after traumatic injury to spinal cord white matter. J Neurotrauma 19:335–342PubMedCrossRefGoogle Scholar
  124. Villa RF, Gorini A (1997) Pharmacology of lazaroids and brain energy metabolism: a review. Pharmacol Rev 49:99–136PubMedGoogle Scholar
  125. Walker JB, Harris M (1993) GM-1 ganglioside administration combined with physical therapy restores ambulation in humans with chronic spinal cord injury. Neurosci Lett 161:174–178PubMedCrossRefGoogle Scholar
  126. Watkins TA, Barres BA (2002) Nerve regeneration: regrowth stumped by shared receptor. Curr Biol 12:R654–R656PubMedCrossRefGoogle Scholar
  127. Webber DJ, Bradbury EJ, McMohan SB, Minger SL (2007) Transplanted neural progenitor cells survive and differentiate but achieve limited functional recovery in the lesioned adult rat spinal cord. Regen Med 2:929–945PubMedCrossRefGoogle Scholar
  128. Wells JE, Rice TK, Nuttall RK, Edwards DR, Zekki H, Rivest S, Yong VW (2002) An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice. J Neurosci 23:10107–10115Google Scholar
  129. Xu J, Fan G, Chen S, Wu Y, Xu XM, Hsu CY (1998) Methylprednisolone inhibition of TNF-alpha expression and NF-kB activation after spinal cord injury in rats. Brain Res Mol Brain Res 59:135–142PubMedCrossRefGoogle Scholar
  130. Xu J, Kim GM, Ahmed SH, Xu J, Yan P, Xu XM, Hsu CY (2001) Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury. J Neurosci 21:92–97PubMedGoogle Scholar
  131. Xu J, Chen S, Chen H, Xiao Q, Hsu CY, Michael D, Bao J (2009) STAT5 mediates antiapoptotic effects of methylprednisolone on oligodendrocytes. J Neurosci 29:2022–2026PubMedCrossRefGoogle Scholar
  132. Yamashita T (2007) Molecular mechanism and regulation of axon growth inhibition. Brain Nerve 59:1347–1353PubMedGoogle Scholar
  133. Yan P, Xu J, Li Q, Chen S, Kim GM, Hsu CY, Xu XM (1999) Glucocorticoid receptor expression in the spinal cord after traumatic injury in adult rats. J Neurosci 19:9355–9363PubMedGoogle Scholar
  134. Yang H-C, Farooqui AA, Horrocks LA (1994a) Effects of glycosaminoglycans and glycosphingolipids on cytosolic phospholipases A2 from bovine brain. Biochem J 299:91–95PubMedGoogle Scholar
  135. Yang H-C, Farooqui AA, Horrocks LA (1994b) Effects of sialic acid and sialoglycoconjugates on cytosolic phospholipases A2 from bovine brain. Biochem Biophys Res Commun 199:1158–1166PubMedCrossRefGoogle Scholar
  136. Yates AJ, Walters JD, Wood CL, Johnson JD (1989) Ganglioside modulation of cyclic AMP-dependent protein kinase and cyclic nucleotide phosphodiesterase in vitro. J Neurochem 53:162–167PubMedCrossRefGoogle Scholar
  137. Yiu G, He Z (2006) Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 7:617–627PubMedCrossRefGoogle Scholar
  138. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96:13496–13500PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Molecular and Cellular BiochemistryThe Ohio State UniversityColumbusUSA

Personalised recommendations